Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Posoleucel, Then Placebo	30
Overall Study	STARTED	Placebo, Then Posoleucel	27
Overall Study	Received Primary Study Treatment	Posoleucel, Then Placebo	28
Overall Study	Received Primary Study Treatment	Placebo, Then Posoleucel	23
Overall Study	Met Cross-over Eligibility Criteria	Posoleucel, Then Placebo	4
Overall Study	Met Cross-over Eligibility Criteria	Placebo, Then Posoleucel	5
Overall Study	Received Cross-over Treatment	Posoleucel, Then Placebo	4
Overall Study	Received Cross-over Treatment	Placebo, Then Posoleucel	5
Overall Study	COMPLETED	Posoleucel, Then Placebo	10
Overall Study	COMPLETED	Placebo, Then Posoleucel	13
Overall Study	NOT COMPLETED	Posoleucel, Then Placebo	20
Overall Study	NOT COMPLETED	Placebo, Then Posoleucel	14

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05179057/flow